drugset / Trial / NCT04320693
Summary
This is an expanded access program (EAP) for eligible participants designed to provide access to IMMU-132.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Sacituzumab Govitecan | Monoclonal antibody | — | Intravenous |